Work

Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors

Year: 2009

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-09-c197

Authors: Neil Faulkner, Patricia M. LoRusso, Tina Guthrie, Jean-Charles Soria, Ratislav Bahleda, Johanna C. Bendell, Jeffrey R. Infante, Christophe Massard, Barbara Van Leeuwen, Jean-Francois Martini, Christian Scheffold, Howard A. Burris

Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute, Institut Gustave Roussy, Tennessee Oncology, Exelixis (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2058038208

Cites:

Cited by: 7

Related to: 10